Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2016

Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2016
Published Jul 13, 2016
78 pages — Published Jul 13, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2016, provides in depth analysis on Toll Like Receptor 3 (CD283 or TLR3) targeted pipeline therapeutics.

The report provides comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3)
- The report reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focu

  
Source:
Document ID
GMDHC0389TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Toll Like Receptor 3 (CD283 or TLR3) Overview71
Therapeutics Development84
  Toll Like Receptor 3 (CD283 or TLR3) Products under Development by Stage of Development81
  Toll Like Receptor 3 (CD283 or TLR3) Products under Development by Therapy Area91
  Toll Like Receptor 3 (CD283 or TLR3) Products under Development by Indication102
Toll Like Receptor 3 (CD283 or TLR3) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Toll Like Receptor 3 (CD283 or TLR3) Products under Development by Companies143
Toll Like Receptor 3 (CD283 or TLR3) Products under Development by Universities/Institutes172
Toll Like Receptor 3 (CD283 or TLR3) Therapeutics Assessment197
  Assessment by Monotherapy/Combination Products191
  Assessment by Mechanism of Action202
  Assessment by Route of Administration222
  Assessment by Molecule Type242
Toll Like Receptor 3 (CD283 or TLR3) Companies Involved in Therapeutics Development268
  Biomics Biotechnologies Co., Ltd.261
  Hemispherx Biopharma, Inc.271
  Idera Pharmaceuticals, Inc.281
  Innate Pharma S.A.291
  Johnson &Johnson301
  MultiCell Technologies, Inc.311
  Oncovir, Inc.321
  Tollys S.A.S331
Toll Like Receptor 3 (CD283 or TLR3) Drug Profiles3426
  Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases Drug Profile341
  Antisense RNAi Oligonucleotide to Agonize TLR-3 for Age Related Macular Degeneration Drug Profile351
  CNTO-3157 Drug Profile361
  Drugs to Activate TLR3 for Atherosclerosis Drug Profile371
  IPH-33 Drug Profile381
  MCT-465 Drug Profile392
  Oligonucleotide to Agonize TLR3 for Oncology Drug Profile411
  Oligonucleotides to Agonize TLR3 for Infectious Disease and Immunology Drug Profile421
  P-7 Drug Profile431
  Poly-ICLC Drug Profile443
  rabies vaccine Drug Profile471
  rintatolimod Drug Profile489
  Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome Drug Profile571
  Small Molecules to Antagonize TLR-3 for Infectious Disease and Immunology Drug Profile581
  Stathmin-1 Drug Profile591
Toll Like Receptor 3 (CD283 or TLR3) Dormant Projects603
Toll Like Receptor 3 (CD283 or TLR3) Discontinued Products631
Toll Like Receptor 3 (CD283 or TLR3) Featured News &Press Releases6413
  Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) in Expert Review of Clinical Pharmacology641
  Jun 06, 2016: Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property651
  Mar 10, 2016: Hemispherx Biopharma Reviews Ampligen Data with National Institute of Neurological Disorders and Stroke651
  Feb 09, 2016: Hemispherx Biopharma Exploring Possible Research Program in Zika Virus Using Ampligen661
  Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant662
  Sep 28, 2015: Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen Formulations681
  Sep 23, 2015: Hemispherx Biopharma Reports Article by Senior Authors from Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen to Multiple Sclerosis691
  Sep 21, 2015: Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome Patients Potentially Predictive of Improved Response to Ampligen701
  Sep 17, 2015: Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study711
  Sep 15, 2015: Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome and Relationship to Disease Symptoms721
  Aug 10, 2015: Hemispherx Enters into an Agreement with myTomorrows for an Early Access Program for Rintatolimod in Europe721
  Jun 25, 2015: Hemispherx Receives the European Patent Office Examining Division s Notice of Intention to Grant the New Composition of Matter Patent Covering Ampligen Formulations731
  May 26, 2015: Hemispherx Biopharma Europe : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Ampligen/Rintatolimod for Ebola Virus Disease741
  May 11, 2015: Hemispherx Biopharma Europe Receives Orphan Medicine Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)741
  Mar 24, 2015: Hemispherx Biopharma Europe Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)752
Appendix772
  Methodology771
  Coverage771
  Secondary Research771
  Primary Research771
  Expert Panel Validation771
  Contact Us771
  Disclaimer781

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Toll-Like-Receptor-3-CD283-or-TLR3-Pipeline-Review-H2-2016-2088-16196>
  
APA:
Global Markets Direct - Market Research. (2016). Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Toll-Like-Receptor-3-CD283-or-TLR3-Pipeline-Review-H2-2016-2088-16196>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.